Mapping and Characterization of Alveolar Cells During Smoking and Chronic Obstructive Disease

NCT05227547 | Recruiting

• 1 other identifier: CoStemCells
• Study Type: interventional
• Target: 186
• Locations: 1 country
• Sites: 4

Brief Summary

To evaluate the regenerative capacities of mesenchymal cells composing the microenvironment of alveolar type 2 cells in a population of patients, undergoing thoracic surgery for suspected cancer, who are smokers with and without COPD compared to non-smokers patients

Conditions

Chronic Obstructive Lung Disease; Chronic Obstructive Pulmonary Disease

Outcome Measures

Primary Outcomes (1)

• Number of alveolar organoids

  Comparison of the number of alveolar organoids formed 21 days after culture of fibroblasts with alveolar type II cells between smokers with and without COPD and non-smoking patients

  through study completion, an average of 3 years

Secondary Outcomes (17)

• Fibroblast proliferation capacity

  through study completion, an average of 3 years

• Differentiation into myofibroblasts

  through study completion, an average of 3 years

• Fibroblast migration capacity

  through study completion, an average of 3 years

• Modulated signaling pathways in isolated fibroblasts between groups

  through study completion, an average of 3 years

• Modulated signaling pathways in endothelial cells between groups

  through study completion, an average of 3 years

Study Arms (1)

Thoracic resection surgery

OTHER

Smokers (active or ex-smokers) and non-smokers with COPD and without COPD undergoing thoracic resection surgery

Other: Thoracic resection surgery

Interventions

Thoracic resection surgery OTHER

Patients undergoing thoracic resection surgery (pneumonectomy, lobectomy, segmentectomy) for cancer or suspected cancer, including smokers (active or ex-smokers) and non-smokers, with COPD and without COPD, and non-smoking patients.

Thoracic resection surgery

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18
• Patient undergoing lung resection surgery (lobectomy, pneumonectomy, segmentectomy) for cancer or suspected cancer
• Acceptance to participate in the protocol
• Affiliated to a social security plan

You may not qualify if:

• Chronic autoimmune disease
• Patient under guardianship or curators
• Neo-adjuvant chemotherapy
• History of thoracic radiotherapy
• Pregnant woman
• Minor patient
• Person not able to consent
• Person deprived of liberty

Sponsors & Collaborators

• Centre Hospitalier Intercommunal Creteil: lead
• Henri Mondor University Hospital: collaborator
• Institut National de la Santé Et de la Recherche Médicale, France: collaborator

Study Sites (4)

Rousseau-Bussac

Créteil, 94000, France

RECRUITING

Hopital Cochin

Paris, 75014, France

ACTIVE NOT RECRUITING

HEGP

Paris, 75015, France

ACTIVE NOT RECRUITING

Hopital Tenon

Paris, 75020, France

ACTIVE NOT RECRUITING

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

JUNG Camille, MD

CONTACT

0145175000; camille.jung@chiccreteil.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 4, 2021
• First Posted: February 7, 2022
• Study Start: October 5, 2022
• Primary Completion (Estimated): October 5, 2030
• Study Completion (Estimated): October 5, 2030
• Last Updated: September 2, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will not share

Locations

FR (4)